Navigation Links
Occlutech Obtains Favourable Ruling in Proceedings Initiated by AGA Medical
Date:3/19/2009

JENA, Germany, March 19 /PRNewswire/ -- Occlutech GmbH today announced that it had defeated a request for insolvency, launched at the Amtsgericht Gera in Germany by its US competitor AGA Medical.

The request by AGA was based on wrongful assumptions about Occlutech, and AGA announced that it had started the said request to recover damages. However, the court - Amtsgericht Gera in Germany - stated, that a proceeding regarding any damages has not yet been started.

"Occlutech intends to maintain a healthy business in vascular intervention based on excellent products for cardiac occlusion as well as coronary and peripheral intervention. We have developed a new range of innovative occluders for treating PFO and ASD in order not to violate the recent German patent ruling," said Tor Peters who was appointed CEO in late January and continued: "We expect to be on the market shortly with the new version."

Occlutech won against AGA Medical in the Patent Court in The Hague in October last year. AGA Medical appealed against this decision by the Patent Court in The Hague and the proceeding is pending.

In Germany, AGA Medical won a patent infringement litigation before the appeal court in Dusseldorf. This decision has no relevance outside Germany though.

"Our response to this is threefold," said Tor Peters. "First we decided to appeal the court's decision and initiated a complaint against the appeal court's revision-disallowance. The appeal court's decision is therefore not final, contrary to what was indicated by our competitor. Secondly, we are pursuing invalidation proceedings to invalidate the relevant AGA Medical patent. The case will be heard in Munich in September. Thirdly, we have developed a version of the occluder that does not violate any ruling. This occluder will be launched in Germany before the summer. Manufacturing, development, marketing and sales outside of Germany have not been impacted and will remain unchanged."

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.

    Press-Contact:
    Tor Peters
    tor.peters@occlutech.se
    +46-42-33-65-20

    Katrin Biedermann
    katrin.biedermann@occlutech.de
    Tel.: +49-3641-67-51-20



'/>"/>
SOURCE Occlutech GmbH
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
2. Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
3. Occlutech Obtains Favourable Court Ruling in Patent Litigation in The Hague Against AGA Medical
4. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
5. Botaneco obtains $2.4 million in funding from AVAC
6. Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
7. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
8. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
9. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
10. PerOs obtains USDA Establishment and Product Licenses for its oral vaccine formulations
11. Biofisica Obtains $2.3 Million in Financing From Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
(Date:10/10/2017)... ... 2017 , ... The Pittcon Program Committee is pleased to ... who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award ... conference and exposition for laboratory science, which will be held February 26-March 1, ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... of medical marijuana products targeting the needs of consumers who are incorporating medical ... takes place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, ...
Breaking Biology Technology:
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext Inc., a global ... of a media edge server, the M820, which features the company,s ... recognition software provided by Tera Probe, Inc., will be showcased during ... at the NAB show at the Las Vegas ... ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):